Choosing the wrong one wastes money and time
Side effects are generally mild, including transient injection-site reactions or mild nausea
As appetite becomes more manageable and routines become easier to keep, many patients notice follow-through improves week to week
Zepbound overtook Novo Nordisk's current injectable obesity therapy Wegovy (semaglutide) in the fourth quarter of 2025, and Novo Nordisk had banked on CagriSema as a near-term growth driver while other candidates in its weight-loss pipeline proceed through clinical testing
A labeled prescription also makes passing through security checkpoints easier
Our programme combines evidence-based nutrition built around the balanced plate model (half vegetables, quarter protein, quarter complex carbohydrates, plus a serving of fat) with habit-change coaching and ongoing clinical oversight